vs

Side-by-side financial comparison of CANTALOUPE, INC. (CTLP) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

CANTALOUPE, INC. is the larger business by last-quarter revenue ($78.7M vs $75.5M, roughly 1.0× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 6.8%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $-614.0K). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 7.7%).

Cantaloupe, Inc., previously known as USA Technologies Inc., is an American company known for its work with ePort cashless acceptance technology running on its patented ePort Connect service, a PCI compliant services. ePort Connect wirelessly facilitates electronic payment options to consumers with credit, debit, or NFC enabled electronic wallets like Apple Pay and Google Pay while providing operators with both telemetry and machine-to-machine (M2M) services. ePort technology is primarily fou...

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

CTLP vs PBYI — Head-to-Head

Bigger by revenue
CTLP
CTLP
1.0× larger
CTLP
$78.7M
$75.5M
PBYI
Growing faster (revenue YoY)
PBYI
PBYI
+21.0% gap
PBYI
27.7%
6.8%
CTLP
More free cash flow
PBYI
PBYI
$15.0M more FCF
PBYI
$14.4M
$-614.0K
CTLP
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
7.7%
CTLP

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
CTLP
CTLP
PBYI
PBYI
Revenue
$78.7M
$75.5M
Net Profit
$-70.0K
Gross Margin
69.3%
Operating Margin
2.0%
22.7%
Net Margin
-0.1%
Revenue YoY
6.8%
27.7%
Net Profit YoY
-101.4%
EPS (diluted)
$0.00
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTLP
CTLP
PBYI
PBYI
Q4 25
$78.7M
$75.5M
Q3 25
$80.9M
$54.5M
Q2 25
$82.6M
$52.4M
Q1 25
$75.4M
$46.0M
Q4 24
$73.7M
$59.1M
Q3 24
$70.8M
$80.5M
Q2 24
$72.7M
$47.1M
Q1 24
$67.9M
$43.8M
Net Profit
CTLP
CTLP
PBYI
PBYI
Q4 25
$-70.0K
Q3 25
$-919.0K
$8.8M
Q2 25
$6.8M
$5.9M
Q1 25
$49.2M
$3.0M
Q4 24
$5.0M
Q3 24
$3.6M
$20.3M
Q2 24
$2.2M
$-4.5M
Q1 24
$4.7M
$-4.8M
Gross Margin
CTLP
CTLP
PBYI
PBYI
Q4 25
69.3%
Q3 25
77.7%
Q2 25
76.5%
Q1 25
77.1%
Q4 24
76.4%
Q3 24
63.9%
Q2 24
77.4%
Q1 24
39.6%
75.5%
Operating Margin
CTLP
CTLP
PBYI
PBYI
Q4 25
2.0%
22.7%
Q3 25
2.0%
17.6%
Q2 25
6.3%
12.7%
Q1 25
9.1%
8.7%
Q4 24
8.4%
22.6%
Q3 24
5.8%
27.4%
Q2 24
4.9%
-4.6%
Q1 24
6.3%
-5.3%
Net Margin
CTLP
CTLP
PBYI
PBYI
Q4 25
-0.1%
Q3 25
-1.1%
16.2%
Q2 25
8.3%
11.2%
Q1 25
65.2%
6.5%
Q4 24
6.7%
Q3 24
5.0%
25.2%
Q2 24
3.0%
-9.6%
Q1 24
6.9%
-11.0%
EPS (diluted)
CTLP
CTLP
PBYI
PBYI
Q4 25
$0.00
$0.26
Q3 25
$-0.02
$0.17
Q2 25
$0.10
$0.12
Q1 25
$0.65
$0.06
Q4 24
$0.07
$0.40
Q3 24
$0.04
$0.41
Q2 24
$0.03
$-0.09
Q1 24
$0.06
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTLP
CTLP
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$53.0M
$97.5M
Total DebtLower is stronger
$37.7M
$22.7M
Stockholders' EquityBook value
$252.5M
$130.3M
Total Assets
$381.9M
$216.3M
Debt / EquityLower = less leverage
0.15×
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTLP
CTLP
PBYI
PBYI
Q4 25
$53.0M
$97.5M
Q3 25
$55.0M
$94.4M
Q2 25
$51.1M
$96.0M
Q1 25
$46.3M
$93.2M
Q4 24
$27.7M
$101.0M
Q3 24
$33.1M
$96.7M
Q2 24
$58.9M
$96.8M
Q1 24
$50.2M
$107.2M
Total Debt
CTLP
CTLP
PBYI
PBYI
Q4 25
$37.7M
$22.7M
Q3 25
$38.3M
$34.0M
Q2 25
$38.7M
$45.3M
Q1 25
$39.2M
$56.7M
Q4 24
$37.0M
$68.0M
Q3 24
$37.3M
$79.3M
Q2 24
$37.5M
$90.7M
Q1 24
$38.1M
$102.0M
Stockholders' Equity
CTLP
CTLP
PBYI
PBYI
Q4 25
$252.5M
$130.3M
Q3 25
$251.8M
$115.3M
Q2 25
$251.0M
$104.7M
Q1 25
$240.7M
$97.1M
Q4 24
$190.1M
$92.1M
Q3 24
$186.2M
$71.1M
Q2 24
$181.7M
$48.5M
Q1 24
$178.8M
$51.0M
Total Assets
CTLP
CTLP
PBYI
PBYI
Q4 25
$381.9M
$216.3M
Q3 25
$389.5M
$202.9M
Q2 25
$381.9M
$194.9M
Q1 25
$370.5M
$196.2M
Q4 24
$303.0M
$213.3M
Q3 24
$312.1M
$220.7M
Q2 24
$335.6M
$205.0M
Q1 24
$319.9M
$214.1M
Debt / Equity
CTLP
CTLP
PBYI
PBYI
Q4 25
0.15×
0.17×
Q3 25
0.15×
0.30×
Q2 25
0.15×
0.43×
Q1 25
0.16×
0.58×
Q4 24
0.19×
0.74×
Q3 24
0.20×
1.12×
Q2 24
0.21×
1.87×
Q1 24
0.21×
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTLP
CTLP
PBYI
PBYI
Operating Cash FlowLast quarter
$3.1M
$14.4M
Free Cash FlowOCF − Capex
$-614.0K
$14.4M
FCF MarginFCF / Revenue
-0.8%
19.1%
Capex IntensityCapex / Revenue
4.8%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$25.8M
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTLP
CTLP
PBYI
PBYI
Q4 25
$3.1M
$14.4M
Q3 25
$7.0M
$9.7M
Q2 25
$9.4M
$14.1M
Q1 25
$22.4M
$3.6M
Q4 24
$522.0K
$15.6M
Q3 24
$-12.0M
$11.0M
Q2 24
$14.3M
$1.0M
Q1 24
$14.7M
$11.2M
Free Cash Flow
CTLP
CTLP
PBYI
PBYI
Q4 25
$-614.0K
$14.4M
Q3 25
$3.5M
$9.7M
Q2 25
$4.3M
$14.1M
Q1 25
$18.6M
$3.6M
Q4 24
$-3.8M
$15.6M
Q3 24
$-15.8M
$11.0M
Q2 24
$8.5M
$1.0M
Q1 24
$11.4M
FCF Margin
CTLP
CTLP
PBYI
PBYI
Q4 25
-0.8%
19.1%
Q3 25
4.4%
17.7%
Q2 25
5.3%
26.8%
Q1 25
24.6%
7.7%
Q4 24
-5.1%
26.4%
Q3 24
-22.3%
13.7%
Q2 24
11.7%
2.1%
Q1 24
16.9%
Capex Intensity
CTLP
CTLP
PBYI
PBYI
Q4 25
4.8%
0.0%
Q3 25
4.2%
0.0%
Q2 25
6.2%
0.0%
Q1 25
5.1%
0.1%
Q4 24
5.8%
0.0%
Q3 24
5.4%
0.0%
Q2 24
7.9%
0.0%
Q1 24
4.8%
0.0%
Cash Conversion
CTLP
CTLP
PBYI
PBYI
Q4 25
Q3 25
1.10×
Q2 25
1.38×
2.41×
Q1 25
0.46×
1.21×
Q4 24
0.10×
Q3 24
-3.36×
0.54×
Q2 24
6.47×
Q1 24
3.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTLP
CTLP

Transaction Processing$47.9M61%
Subscription Revenue$21.8M28%
Products$9.0M11%

PBYI
PBYI

Segment breakdown not available.

Related Comparisons